Added to YB: 2026-04-22
Pitch date: 2026-04-20
IOVA [neutral]
Iovance Biotherapeutics, Inc.
-2.37%
current return
Author Info
No bio for this author
Company Info
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Market Cap
$1.6B
Pitch Price
$3.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.91
P/E
-3.53
EV/Sales
5.10
Sector
Biotechnology
Category
growth
Monthly Core Conviction #1: The Full M&A Book - Iovance Biotherapeutics, Inc.
IOVA (update): Commercial Amtagvi TIL therapy for melanoma w/ multi-yr label expansions (cervical, lung, H&N). Capital-intensive center rollout is overhang. Cash runway into 2H26/Q3'27 w/ cost cuts. Classic big pharma cell therapy bolt-on if rollout accelerates. $1.6B mcap vs peak commercial potential attractive
Read full article (1 min)